This week, The Pharmaceutical Journal has reported on the first UK guidance for polyendocrine metabolic ovarian syndrome, a call to reclassify the morning-after pill as a general sales list item, funding for community pharmacy obesity care, the stalling of a community pharmacy PrEP pilot in Wales, and medicine cash flow issues in both primary and secondary care. Read on for more health news you might have missed this week.